NodThera Looks To Compete In Long-Awaited Inflammasome Field With Parkinson’s Therapy
Will Face Competition From Roche
NodThera is a pioneer in the field of NLRP3 inflammasome inhibitors, and after overcoming drug development setbacks, believes it can compete in a field alongside rivals such as Roche, Novartis and Novo Nordisk.
